What's New

4523

Eisai Co., Ltd.

Information Meeting

Representative Corporate Officer and CEO Haruo Naito
3659

NEXON Co., Ltd.

Q4 2019 Earnings Presentation

President and Chief Executive Officer Owen Mahoney
7013

IHI Corporation

Financial Results for Third Quarter FY2019 (for the year ending March 31, 2020)

Finance and Accounting Division, General Manager Seiji Maruyama
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 3rd Quarter Financial Results for Fiscal Year 2019(Conference call 10:00pm-11:00pm JST)

Chief Financial Officer
Costa Saroukos
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 3rd Quarter Financial Results for Fiscal Year 2019

President and Chief Executive Officer
Christophe Weber
4523

Eisai Co., Ltd.

Q3 FY2019 (Fiscal Year Ending March 31, 2020) Financial Results Presentation

Executive Vice President Chief Financial Officer Chief IR Officer Ryohei Yanagi
4204

SEKISUI CHEMICAL CO., LTD.

Presentation of Financial Results for the 3rd Quarter of FY2019

Representative Director, Senior Managing Executive Officer, Head of Business Strategy Department Keita Kato
4503

Astellas Pharma Inc.

Q3/FY2019 financial Results ended December 31, 2019

Representative Director, Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer Naoki Okamura
8604

Nomura Holdings, Inc.

Third Quarter Operating Results for Fiscal Year Ending March 2020

CFO Takumi Kitamura
8252

Marui Group., Ltd.

MARUI IR DAY 2019. 12

Hiroshi Aoi President and Representative Director, MARUI GROUP CO., LTD.
4503

Astellas Pharma Inc.

R&D Meeting

President and Chief Executive Officer Kenji Yasukawa, Ph.D.
4503

Astellas Pharma Inc.

ACQUISITION OF AUDENTES

Representative Director, Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer Naoki Okamura
8604

Nomura Holdings

Nomura Investment Forum 2019

Group CEO Koji Nagai
8630

Sompo Holdings, Inc.

Progress of Mid-term Management Plan

President(Group CEO) Kengo Sakurada
8766

Tokio Marine Holdings, Inc.

Tokio Marine Group Business Strategy

President and Group CEO Satoru Komiya
8252

Marui Group.Ltd.

Six Months Ended September 30 , 2019 Financial Results and Future Developments

Hiroshi Aoi President and Representative Director, MARUI GROUP CO., LTD.
4502

Takeda Pharmaceutical Company Limited

R&D Day and Plasma-Derived Therapies Day

President & CEO Takeda
Christophe Weber
4536

Santen Pharmaceutical Co., Ltd.

Investor Meeting on Q2 FY2019 Results

President & Chief Operating Officer Shigeo Taniuchi
4204

SEKISUI CHEMICAL CO., LTD.

Presentation of Financial Results and Progress under Management Plan for the 2nd Quarter FY2019

4502

Takeda Pharmaceutical Company Limited

Earnings Conference for the 2nd Quarter of Fiscal Year 2019(Conference call 9:00pm-9:45pm JST)

Chief Financial Officer Costa Saroukos
4502

Takeda Pharmaceutical Company Limited

Earnings Conference for the 2nd Quarter of Fiscal Year 2019

President and Chief Executive Officer Christophe Weber
4503

Astellas Pharma Inc.

Q2/FY2019 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2019

President and CEO Kenji Yasukawa, Ph.D.
8604

Nomura Holdings, Inc.

Second Quarter Operating Results for Fiscal Year Ending March 2020

CFO Takumi Kitamura
4502

Takeda Pharmaceutical Company Limited

IR meeting with analysts and investors with Julie Kim, President of Takeda’s Plasma Derived Therapies Business Unit

4536

Santen Pharmaceutical Co., Ltd.

R&D Day 2

President and Chief Operating Officer Shigeo Taniuchi
4204

SEKISUI CHEMICAL CO., LTD.

Presentation of Financial Results for the 1st Quarter of FY2019

Keita Kato Representative Director, Senior Managing Executive Officer, Head of Business Strategy Department
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 1st Quarter Financial Results for Fiscal Year 2019

President and Chief Executive Officer
Christophe Weber
4536

Santen Pharmaceutical Co., Ltd.

R&D Day

Senior Corporate Officer, Head of Corporate Development Division, Head of China Business Satoshi Suzuki
8630

Sompo Holdings, Inc.

Progress of Mid-term Management Plan and FY2019 to FY2020 of the Plan

President(Group CEO) Kengo Sakurada
8766

Tokio Marine Holdings, Inc.

Tokio Marine Group Business Strategy

President and Group CEO Tsuyoshi Nagano
8252

MARUI GROUP CO., LTD.

MARUI IR DAY

President and Representative Director Hiroshi Aoi
8252

MARUI GROUP CO., LTD.

Financial Results Briefing for the Fiscal Year Ended March 31, 2019, and Future Outlook

President and Representative Director Hiroshi Aoi
4507

SHIONOGI & CO., LTD.

FY2018 Financial Results (April 2018 - March 2019)

President and CEOIsao Teshirogi, Ph.D.
4502

Takeda Pharmaceutical Company Limited

Earnings Conference for the Financial Results for Fiscal Year 2018(part 1)

President and Chief Executive Officer Christophe Weber
4502

Takeda Pharmaceutical Company Limited

Earnings Conference for the Financial Results for Fiscal Year 2018 (part 2)

President and Chief Executive Officer Christophe Weber
4536

Santen Pharmaceutical Co., Ltd.

Investor meeting on full year earnings

President & Chief Operating Officer Shigeo Taniuchi
4204

SEKISUI CHEMICAL CO., LTD.

Presentation of Financial Results and Progress under Management Plan for FY2018

Teiji Koge,President
4523

Eisai Co., Ltd.

Eisai Scientific Meeting 2019

8604

Nomura Holdings, Inc.

Investor Day

koji Nagai Group CEO
4507

SHIONOGI & CO., LTD.

R&D presentation

President and CEO Isao Teshirogi ,Ph.D
4507

SHIONOGI & CO., LTD.

3rdQuarter of Fiscal 2018 Financial Results Conference Call

Kohji Hanasaki, Ph.D. Senior Executive Officer, Senior Vice President, Finance & Accounting Department
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 3rd Quarter Financial Results for Fiscal Year 2018 (Part 2)

Chief Financial Officer Costa Saroukos
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 3rd Quarter Financial Results for Fiscal Year 2018 (Part 1)

President and Chief Executive Officer Christophe Weber
4502

Takeda Pharmaceutical Company Limited

Meeting regarding Acquisition of Shire plc by Takeda

President and Chief Executive Officer Christophe Weber
8252

MARUI GROUP CO., LTD.

MARUI IR DAY 2018

Hiroshi Aoi President and Representative Director, Representative Executive Officer
8766

Tokio Marine Holdings, Inc.

Mid-Term Business Plan "To Be a Good Company 2020" FY2018 Business Plan Update

President and Group CEO Tsuyoshi Nagano
4536

Santen Pharmaceutical Co., Ltd.

Investor Meeting on Q2 FY2018 Results

President & Chief Operating Officer (COO) Shigeo Taniuchi
4502

Takeda Pharmaceutical Company Limited

Earnings Conference for the 2nd Quarter of Fiscal Year 2018

President and Chief Executive Officer Christophe Weber
4502

Takeda Pharmaceutical Company Limited

TAKEDA R&D INVESTOR DAY 2018

Christophe Weber
President and Chief Executive Officer
8630

Sompo Holdings, Inc.

Sompo International Overview

Mike McGuire Sompo International Holdings CFO
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 1st Quarter Financial Results for Fiscal Year 2018

President and Chief Executive Officer Christophe Weber
4502

Takeda Pharmaceutical Company Limited

Conference for the Announcement of "Financial Results for Fiscal Year 2017"

President and Chief Executive Officer
Christophe Weber
4502

Takeda Pharmaceutical Company Limited

Takeda to Acquire Shire-Accelerating Takeda's Transformation to Deliver More for Patients

Christophe Weber President and CEO
4502

Takeda Pharmaceutical Company Limited

Takeda to Acquire Shire-Accelerating Takeda's Transformation to Deliver More for Patients

President and CEO
Christophe Weber
4204

SEKISUI CHEMICAL CO., LTD.

Presentation of Medium-term Management Plan SHIFT 2019-Fusion- (FY2017-FY2019)

President Teiji Koge,

Precautions in use

Nomura IR assumes no responsibility for correctness, validity or any other nature of the contents on this server.
No act such as alteration, modification or addition to the contents is permitted.
Since the contents on this server are not intended to solicit investment, our company has no liability for any trouble related to investment made by any audience based on the contents of this site. Investors are required to decide at their own discretion.
Nomura IR assumes no responsibility for correctness, validity or any other nature of information, including its format and details, obtained from any site linked from our site.